Title of Invention	DERMOPHARMACEUTICALLYAND COSMETICALLY ACTIVE
Abstract	The invention relates to oligopeptides and derivatives thereof, to peptide analogs and deriva-tives thereof and to pharmaceutically acceptable salts of the compounds, which correspond to genera] formula (I), wherein: Rl represents H, -C(O)-R7, -SO2-R7, -C(O)-OR7 or -C(O)-N(R7)2; R2 represents, independent of one another, H or -(C1-C4) alkyl; R3 and R6 represent, independent of one another, -(CH2)q-N(R1)R8; R4 and R5 represent, independent of one another, CH2-OR2, -CH(CH3)OR8 or CH2-CHrOR8; R7 represents hydrogen, optionally substituted (C1-C19) alky], optionally substituted C1-C19 alkenyl, phenyl-C1-C4 alkyl whose phenyl radical is optionally substituted with amino in the p position; R8 represents H, -(C1-C4) alky], -C(O)-R7, -C(O)-OR7, -C(O)-N(R7)2 or -SC2-R7; X represents oxygen (-O-) or -NH- or; XR7, with X = O, also represents the esters of a-tocopherol, tocotrienol or retinol or the carboxylic acid (with R7 = H); m, n, p represent, independent of one another, zero or 1, and;q in R3and in R6 represents, independent of one another, an integer from 1 to 4, with the provision that the following conditions do not simultaneously occur R4 = -CH (CH3) -OH and R5 = -CH (CH3) -OH and R6 = -(CH2)4-NH2. The invention also relates to dermopharmaceutically and cosmetically active compositions containing at least one compound of formula (I).

Title of Invention

DERMOPHARMACEUTICALLYAND COSMETICALLY ACTIVE

Abstract

The invention relates to oligopeptides and derivatives thereof, to peptide analogs and deriva-tives thereof and to pharmaceutically acceptable salts of the compounds, which correspond to genera] formula (I), wherein: Rl represents H, -C(O)-R7, -SO2-R7, -C(O)-OR7 or -C(O)-N(R7)2; R2 represents, independent of one another, H or -(C1-C4) alkyl; R3 and R6 represent, independent of one another, -(CH2)q-N(R1)R8; R4 and R5 represent, independent of one another, CH2-OR2, -CH(CH3)OR8 or CH2-CHrOR8; R7 represents hydrogen, optionally substituted (C1-C19) alky], optionally substituted C1-C19 alkenyl, phenyl-C1-C4 alkyl whose phenyl radical is optionally substituted with amino in the p position; R8 represents H, -(C1-C4) alky], -C(O)-R7, -C(O)-OR7, -C(O)-N(R7)2 or -SC2-R7; X represents oxygen (-O-) or -NH- or; XR7, with X = O, also represents the esters of a-tocopherol, tocotrienol or retinol or the carboxylic acid (with R7 = H); m, n, p represent, independent of one another, zero or 1, and;q in R3and in R6 represents, independent of one another, an integer from 1 to 4, with the provision that the following conditions do not simultaneously occur R4 = -CH (CH3) -OH and R5 = -CH (CH3) -OH and R6 = -(CH2)4-NH2. The invention also relates to dermopharmaceutically and cosmetically active compositions containing at least one compound of formula (I).

Full Text	- 1 - Dermopharmaceutically and cosmetically active oligopeptides The present invention relates to pharmaceutically, dermopharmaceutically and cosmetically active oligopeptides, to derivatives thereof, to peptide analogs and derivatives thereof as well as to the use thereof in dermopharmaceutically and cosmetically active compositions. The basic mechanism of skin aging is known to take place in the extracellular matrix, the so-called basal lamella/ when situated at the intersection between epithelium and connective tissue. Regeneration of the extracellular matrix is highly important as it considerably influences the behaviour of those cells that are in contact with it, in particular their growth, migration, proliferation, form and functions. An age-related reduction of collagen synthesis by fibroblasts occurs in this extracellular matrix, the consequence of which being a reduced number of chemical substances secreted by these cells. As skin proteins consist by approx. 80% of collagen, already a small natural decrease of the collagen concentration in the tissue may have clear consequences on the mechanical and physiological properties of skin. Katayama et al. (The Journal of Biological Chemistry, Vol. 268, No. 14, pages 9941-9944, 1993) found that the minimal subfragment sequence for stimulating collagen and fibronectin is represented by the pentapeptide Lys-Thr-Thr-Lys-Ser. Sequences with four amino acids or less have a slighter or no stimulating effect. - 2 - The European patent application WO 00/15188 describes the effect of the palmitoylated pentapeptide Palm-Lys-Thr-Thr-Lys-Ser as a component tor treating skin aging, accelerating wound healing and improving skin moisturizing. It has been found that selected, new oligopeptides and derivatives thereof as well as peptide analogs and derivatives thereof (in the following referred to as ,,compounds of the present invention") are surprisingly highly pharmaceutically and/or cosmetically effective and are particularly appropriate for use in dermopharmaceutically and/or cosmetically effective compositions. The compounds of the present invention diffuse rapidly and in sufficient concentration through the cell membrane up to the intracellular site of action, where they lead to a clearly increased production of collagen and fibronectin. Thus, the compounds of the present invention exert a surprisingly positive and stimulating effect on the extracellular matrix which decisively influences the mechanical and physiological appearance of skin. In particular, the compounds of the present invention induce a much more rapid and stronger stimulation of collagen synthesis than known so far for other compounds from the state of the art. The quicker and stronger stimulation of collagen synthesis by the compounds of the present invention is probably the result of a synergic effect which is obtained by reduction, of the molecular mass, introduction of N-methyl groups in amino acids and modification of amino acids with, e.g., fatty acid esters. However, the present invention is not bound to this explanation. - 3 - The present invention is defined in the claims and relates in particular to selected, new oligopeptides and derivatives thereof, peptide analogs and derivatives thereof, as well as pharmaceutically acceptable salts of these compounds, thereby characterized that these compounds correspond to general formula (I) wherein R1 represents H, -C(O)-R7, -SO2-R7, -C(0)-OR7 or -C (0) -N (R7) 2, R2 represents, independent of one another, H or -{C1-C4)- alkyl, R3, R6 represent, independent of one another, - (CH2)q-N (R1) R8, R4, R5 represent, independent of one another, -CH2-OR2, CH(CH3)OR8 or -CH2-CH2-OR8, R7 represents hydrogen, (C1-C19)-alkyl optionally substituted once or several times, independent of one another, with halogen, hydroxy, carboxyl, amino, mercapto, 1,2-dithiolanyl, and/or sulfo; optionally substituted (C1-C19)-alkenyl; phenyl- {C1-C4)-alkyl, whose phenyl radical is optionally substituted with amino in the para position; or R8 represents H, - (C1-C4) -alkyl, -C (0) -R7, -C (0) -OR7, -C (0) - N(R7)2 or -SO2-R7 X represents oxygen (-0-) or -NH-; or XR7, with X = 0, also represents the esters of a-tocopherol, tocotrienol or retinol or the carboxylic acid (with R = H) , m, n, p represent, independent of one another, zero or 1 and - 4 - q in R3 and R6 represents, independent of one another, an integer from 1 to 4, with the provision that the following conditions do not simultaneously occur: R4 = -CH{CH3)-OH and R5 = -CH(CH3)-OH and R6 = ~(CH2)4-NH2. Preferably, the following conditions do not simultaneously occur: R4 = -CH2-OH or -CH(CH3)-OH and R5 = -CH(CH3)-OH and R6 = -(CH2)4-NH2. Preferably, the following conditions do not simultaneously occur: R2 = H and R4 = -CH2-OH or -CH (CH3) -OH and R5 = -CH The compounds of "formula (I) comprise dipeptides, tripeptides, tetrapeptides and pentapeptides of the corresponding amino acids and derivatives thereof according to the definitions of R1, R2, R7 and R8, as well as corresponding peptide analogs. The amino acid residues in general formula (I), which contain the substituents R3 or R6, are derived from lysine (Lys) , ornithine (Orn) , 2,4-diaminobutyric acid (Dab) or 2,3-diaminopropionic acid (Dap) and are residues of these amino acids or amino acid derivatives. The amino acid residues in general formula (I), which contain the substituents R4 or R5, are derived from serine (Ser) , threonine (Thr), homo serine [H2N-CH ( (CH2) 2-0H)COOH, (HSe)] and are residues of these amino acids or amino acid derivatives. The following table shows from which amino acids the compounds of the above formula (I) are derived: - 5 The residue [R1 (N (R2) CH (R3) C (0) -] is preferably derived from lysine. The residue [-N (R2) CH (R4) C (0) -] at position [-N N (R2)CH (R5)C(0)-] is preferably derived from threonine. The residue [-N (R2) CH (R5) C (0)-] is preferably derived from threonine. The residue [-N (R2) CH (R6) C (0) -] is preferably derived from ornithine, 2,4-diaminobutyric acid (Dab), and 2,3-diaminopro- pionic acid (Dap). The terminal residue [- derived from serine. The compounds of formula {I) preferably contain the following sequences: Sequence 1: -Ser-Ser-Orn- Sequence 2: -Thr-Thr-Orn- Sequence 3: -Thr-Thr-Dab- Sequence 4: -Thr-Thr-Dap- The compounds with the sequences -Ser-Ser-Orn-, Lys-Thr-Thr- Orn-Ser, Lys-Thr-Thr-Dab-Ser and Lys-Thr-Thr-Dab-Ser, as well as the sequences correspondingly derivatized with the substituents R1, R2, R7 and R8 are particularly preferred. - 6 - Further preferred polypeptides enclosed by formula {I) are mentioned in the text. Preferred compounds of formula (I) are also those wherein m = zero, when n or p = zero. The terms ,,peptides" and ,,oligopeptides" above all comprise naturally occurring amino acids, peptides and oligopeptides, respectively. Peptide analogs mean synthetically modified amino acids, peptides and oligopeptides, respectively, e.g. with a methyl group at the nitrogen atom (CH3-N=) . Derivatives within the present invention particularly mean amino acids, peptides and oligopeptides, respectively, the terminal amino group or carboxyl group of which has been further converted, e.g. wherein the terminal carboxyl group has been esterified. The compounds of formula (I) are particularly appropriate as pharmaceutical, dermopharmaceutical and/or cosmetic active ingredients for the preparation of pharmaceutically, dermopharmaceutically and/or cosmetically active compositions, in particular for increasing the collagen and fibronectin production in human skin. Moreover, the present invention relates to a method for preparing the compounds of the present invention and salts thereof and their use as pharmaceutical, dermopharmaceutical and/or cosmetic active ingredients, as well as pharmaceutically, dermopharmaceutically and/or cosmetically active compositions which contain at least one compound of the present invention. - 7 - Furthermore, the present invention relates to the use of the compounds of the present invention for preparing a wound healing- and moisturizing-stimulating drug as well as to a method for delaying or treating skin aging, in particular the formation of wrinkles, which comprises applying a compound of the present invention and/or a composition of the present invention on the skin. The above used, general terms are defined as follows: Halogen means chlorine, bromine or iodine, preferably fluorine. Alkyl, as a group per se or as a structural element of an alkoxy function, comprises linear as well as branched alkyl groups. Examples thereof are methyl, ethyl, propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-undecanyl, n-dodecanyl, n-tridecanyl,, n-hexadecanyl, n-heptadecanyl, n-octadecanyl or n-nonadecanyl as unbranched residues and isopropyl, tert.butyl, isobutyl, sec.butyl, isoamyl as branched residues. R2 and/or R8 as alkyl preferably means methyl, ethyl and propyl, preferably methyl. If R7 as a part of R1 means or contains an alkyl residue, it preferably represents alkyl with 8 to 22 C atoms, preferably with 14 to 17 C atoms. If XR7 contains an alkyl residue, it preferably means alkyl with 1 to 22 C atoms, preferably with 1 to 4 C atoms. Alkenyl has the denotation of a mono- or poly-unsaturated, optionally substituted alkyl group, such as e.g. 8 (Z) -heptadecenyl, 8(Z), 11 (Z)-heptadecadienyl, 4 (Z),7(Z),10(Z), 13(Z)-nonadecatetraenyl, 8(Z)-11-hydroxyoctadecenyl. - 8 - -Tocopheryl means (D)-, The compounds of formula (I) together with acids can form mono- or polyvalent, homogeneous or mixed salts, e.g. with inorganic acids, such as hydrochloric acid, bromhydric acid, sulfuric acid or phosphoric acid; or with appropriate organic aliphatic saturated or unsaturated carboxylic acids, e.g. aliphatic mono- or dicarboxylic acids, such as formic acid, acetic acid, trifluoroacetic acid, trichloroacetic acid, propionic acid, glycolic acid, succinic acid, fumaric acid, malonic acid, maleic acid, oxalic acid, phthalic acid, citric acid, lactic acid or tartaric acid; or with aromatic carboxylic acids, such as benzoic acid or salicylic acid; or with aromatic-aliphatic carboxylic acids, such as mandelic acid or cinnamic acid; or with heteroaromatic carboxylic acids, such as nicotinic acid; or with aliphatic or aromatic sulfonic acids, such as methanesulfonic acid or toluenesulfonic acid. Dermatologically tolerated salts, in particular salts with acetic acid and/or lactic acid, are preferred. The compounds of general formula (I) also comprise the possible isomeric forms as well as mixtures thereof, e.g. racemic mixtures and mixtures of rotamers. The amino acids mentioned in formula (I) can have an L or D configuration, or represent a mixture of both configurations. - 9 - In particular, Thr may also represent the isomeric forms allo-Thr, D-Thr or D-allo-Thr or a mixture of Thr with D-Thr or allo-Thr with D-allo-Thr at the respective position in the sequence. Among the compounds of formula (I), the following denotations or the following groups of compounds, respectively, are preferred, wherein R1 represents hydrogen, -C{O)-R7, -SO2-R7, -C(O)-OR7 or -C(0)-N(R7)2, preferably wherein R1 represents hydrogen, -C(O)-R7 or -SO2-R7, preferably hydrogen or -C(O)-R7 R2 represents, independent of one another, hydrogen or methyl R3, R6 represent, independent of one another, - R7 preferably represents hydrogen, methyl, ethyl, propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-undecanyl, n-dodecanyl, n-tridecanyl, n-tetradecanyl, n-pentadecanyl, n-hexadecanyl, n-heptadecanyl, n-octadecanyl or n-nonadecanyl, isopropyl, tert.butyl, isobutyl, sec.butyl, isoamyl, phenyl, t-butylphenyl, tolyl, 1- or 2-naphthyl, perfluorobutyl, pentadecafluoroheptyl, ( + )- or (-)-bornan-2-onyl, 8(Z)-heptadecenyl, 8(Z),11 - 10 - R8 represents hydrogen, C1-C4-alkyl or -C(O)-R7, preferably hydrogen or methyl. X represents oxygen, -NH-, preferably oxygen, XR , with X = O, also represents the esters of ct-tocopherol, tocotrienol or retinol or the carboxylic acid (with R7 = H), preferably the carboxylic acid, m, n, p represent, independent of one another, zero or 1, and q in R3 and R6 represents, independent of one another, the integer 1, 2, 3 or 4. R7-C(O)- most preferably represents the residue of a saturated or unsaturated fatty acid with 6, 8, 10, 12, 14, 16 or 18 C atoms, preferably the corresponding residue of a saturated fatty acid, preferably the corresponding residue of caprylic acid [CH3- (CH2) 6-C Representative examples of compounds of formula (I) are listed in Table 5 (after Example 7). The compounds of the present invention can be manufactured according to methods known per se in peptide chemistry. The preferred procedure comprises fully assembling the compound of the present invention, e.g. a compound of formula (I) , optionally splitting off the remaining protective group(s) and optionally acylating a free amino group and/or converting the obtained compound into an acid addition salt and/or an obtained acid addition salt into the corresponding conjugate base or into another salt. - 11 - The compounds of the present invention can be used for the preparation of a dermopharmaceutically and/or cosmetically active composition. Such compositions contain an effective quantity of at least one compound of the present invention or a salt thereof, in the range from 0.5 ppm to 5,000 ppm (w/w), preferably between 1 ppm and 1000 ppm (w/w) , calculated on the weight of the compound of the present invention and of the bulking agent(s). The compounds of the present invention can be used as a solution, a dispersion, an emulsion or encapsulated in carriers, such as e.g. in macro-, micro- or nanocapsules, in liposomes or chylomicrons, or enclosed in macro-, micro- or nanopar tides or in micro fungi or adsorbed on powdered organic polymers, talc, bentonite and further inorganic carriers. The compounds of the present invention can be used in any galenic form, such as emulsions, milks, lotions, ointments, gelatinous and viscous, lifting and emulsifying polymers, pomades, shampoos, soaps, gels, powders, sticks, sprays, body oils, face masks or a plaster for transdermal application. The compounds of the present invention can be used with any further, commonly used ingredient, such as extraction lipids and/or synthetic lipids, gelatinous and viscous, lifting and emulsifying polymers, water- or fat-soluble active agents, plant extracts, tissue extracts, marine extracts, sun-protective agents, antioxidants, water-retaining and barrier substances as well as skin-revitalizing agents. The compounds of the present invention are used in cosmetic applications to enhance wound healing_and hy_dx_at_ion, and in all skin care products, in particular against the formation - 12 - and aggravation of wrinkles and against all consequences of natural or accelerated (sun rays, pollution) skin aging. The compounds of the present invention as well as the cosmetic and dermopharmaceutical compositions containing same can be used for the preparation of a drug to promote wound healing and hydration, and for all skin care products, in particular against the formation and aggravation of wrinkles and against all consequences of natural or accelerated (sun rays, pollution) skin aging. The present invention also relates to a method for delaying or treating skin aging, in particular wrinkle formation, which comprises the application on the skin of a compound of the present invention. Analogously, the present invention relates to a method for accelerating wound healing and/or improving skin hydration, which comprises the application on the skin of a compound of the present invention. The following examples illustrate the invention without limiting its scope. The following abbreviations are used in the text and in Examples 1-7: AcOH: Acetic acid Boc: tert.-Butyloxycarbonyl Dab: 2,4-Diaminobutyric acid Dap: 2,3-Diaminopropionic acid DBU: 1,8-Diazabicyclo[5,4,0]undec-7-ene(1,5-5) DIPEA: Diisopropylethylamine DMEM: Dulbecco's Modified Eagle Medium Et: Ethyl FCS: Fetal Calf Serum HSe: Homoserine - 13 - Hyp: Hydroxyproline Gly: Glycine Lipoyl: a-D,L-Lipoic acid Me: Methyl MEM: Minimal Essential Medium N-Me-Ser: N-Methyl-Serine N-Me-Thr: N-Methyl-Threon.ine NMM: N-Methylmorpholine Orn: Ornithine Palm: Palmitoyl PBS: Phosphate buffered saline Pr: Propyl RT: Room temperature TBTU: O-(Benzotriazol-1-yl)-N,N,N' ,N'-tetramethyluronium tetrafluoroborate tBu: t-Butyl TFA: Trifluoroacetic acid TGF-p(beta)1: Transforming Growth Factor-beta(p) Example 1: Determination of the stimulation of collagen synthesis type I+III in fibroblast cell cultures (ATCC CCL110) by treatment with the oligopeptide derivatives of the present invention. Method: The collagen I and III content in fibroblasts is measured with the Sirius Red microassay. The quantitative determination of collagen is carried out after 24 hours of incubation with the corresponding oligopeptide derivatives. The extracellularly accumulated collagen is determined. Vitamin C and TGF-beta-1 are used as positive controls. - 14 - Method: ATCC CCL110 fibroblasts are incubated in culture medium at a density of approx. 125,000 cells/well in 6-well cell culture plates for 2 days (37°C/5%CO2) . Afterwards, the medium is discarded and washed twice with PBS, whereupon 1 ml of test medium with corresponding test substances is added. After . incubation with test substance under culture conditions (37°C/5%CO2) for further 24 hours, the extracellular collagen is measured with the Sirius Red assay. Sirius Red assay extracellular: After the incubation period, the total volume of test medium (1 ml) is transferred into a flat-bottom 24-well plate and dried overnight at 55°C. The samples are fixed with 1 ml/well of Bouin's fluid for 1 hour at room temperature (RT) . The fixing solution is discarded and the plates are washed 2-3 times with water. After drying of the plates, 1 ml of Sirius Red dye reagent is added. The samples are shaken for 1 hour at RT on a microplate agitator at moderate intensity. Afterwards, the Sirius Red dye reagent is discarded and the plates are washed with 0.01N HCl. The tinted material is dissolved in 0.3 ml of 0.IN NaOH solution and shaken on a microplate agitator for 1 hour at Rf. 200 [il of solution is transferred into a flat-bottom 96-well plate and the optical density is measured at 540 nm against 0.1N NaOH solution as the blank. Material: - 15 - Culture medium: MEM + 10% FCS + 100 IU/ml penicillin + 0.1 mg/ral streptomycin + 1 mM non essential amino acids + 1 mM Na-pyruvate + 2 mM L-glutamine. Test medium: DMEM without phenol red (AMIMED) + 100 IU/ml penicillin + 0.1 mg/ml streptomycin + 80 ng/ml beta (p)- aminopropionitrile. Dilution of the substances: Vitamin C 100 mM (SIGMA A4034) is diluted to 50 ng/ml in the test medium. Transforming growth factor TGF 1 1 ng/ml (SIGMA T1654) is diluted to 0.1 ng/ml in the test medium. The oligopeptide derivatives of the present invention are prepared in a regular concentration of 10 mM and diluted to 50 fiM in the test medium. Reagents for the Sirius Red microassay: Sirius Red F3BA dye reagent as the stock solution 1 mg/ml in saturated aqueous picric acid solution. Bouin's fluid: 15 ml of saturated aqueous picric acid solution + 5 ml of formaldehyde + 1 ml of acetic acid. The results are shown in Table 1. Table 1 Results, quantitative determination of collagen type I+III after 24 hours: - 16 - Example 2: Determination of the fibronectin content after treatment with the oligopeptide derivatives of the present invention Method: The fibronectin (laminin or collagen VII) content in the fibroblast cells is determined by immuno-dot blotting. Cultivation and incubation of the cells are carried out in the same way as described in Example 1. Afterwards, the cells are lysed and the lysates (0.5 ml) are blotted on a nitrocellulose sheet in a prepared bio-dot device. The sheets are then incubated with a specific primary antibody to human fibronectin according to the western blotting method. A conjugate with alkaline phosphatase is used as the secondary antibody. The intensity of the bands is visually determined semi-quantitatively after dying and stopping of the reaction. The results are shown in Table 2. Table 2 Results, quantitative determination of fibronectin (or laminin V or collagen type VII) after 24 hours of incubation: - 17 - Example 3: Formulation of an ointment Method: Ingredients 1-5 (A) are heated to 70°C. Ingredients 6-7 (B) are heated to 75°C. Under stirring B is added to A, cooled to 50°C, homogenized and cooled to 30°C. Afterwards, ingredients 8-9 (C) and ingredient 10 (D) are added one after the other and stirred cold. The formulations are shown in Table 3. 10 Table 3 Example 4: Formulation of a gel Method: Ingredients 2-6 (A) are dissolved one after the other in deionized water. After adjusting the pH to 6.0 with ingredient 7 (B), ingredient 8 (C) is added. The formulations are shown in Table 4. - 18 Table 4 Examples 5-7: The following embodiments 5-7 describe the synthesis of the compounds of formula (I) of the present invention and of salts of such compounds. The eluates and products obtained according to the examples are analysed using proton NMR, HPLC-electrospray MS or elementary analysis. The compounds can be manufactured according to known methods described hereinafter (general instructions from M. Bodanszky "The Practice of Peptide Synthesis", Springer, 2nd Edition, 1994). Accordingly, the amino acid, e.g. serine, is bound to a resin at the carboxy terminal end in a solid-phase synthesis, whereby its amino group is protected by a protective group, e.g. by the Fmoc protective group. The side chain is protected with, e.g., Boc or t-butyl. If necessary, the protective groups are selectively split off in order to link up the further amino acid derivatives with the reagents commonly used in peptide synthesis until the desired chain is completely built up. Afterwards, the peptide or peptide analog, respectively, is split off from the resin at the carboxy terminal end and this carboxy terminal end is - 19 - connected with varying C(O)-R7, SO2-R7, C(O)-OR7 or C(O)-N(R7)2 residues, whereupon the protective groups are removed. Example 5: H-Lys-Thr-Ser-Orn-Ser x 3 TFA Synthesis of H-Lys(Boc)-Thr(tBu)-Ser(tBu)-Orn(Boc)-Ser(tBu)- OH x TFA (5a): In a typical solid-phase synthesis protocol, the pentapeptide is obtained by repetitive coupling of 18.7 g {14.0 mmol, charge: 0.75 mmol/g) of commercial H-Ser(tBu)-chlorotrityl resin with 16.8 mmol of the amino acids Fmoc-Orn (Boc) -OH, Fmoc-Thr(tBu)-OH (2x), Fmoc-Lys(Boc)-OH, 18 mmol TBTU, 33.6 mmol collidin and unblocking with 1% DBU in DMF (2x5 min) , splitting from the resin with 1% TFA in dichloromethane and purification over Sephadex LH20®, yield: 9.3 g (64%). Synthesis of H-Lys-Thr-Ser-Orn-Ser-OH x 3TFA (5b): 9.3 g of 5a is stirred for 1 hour at RT in a mixture composed of 59 ml of TFA, 1.25 ml of water and 1.25 ml of triisopropylsilan. After reduction to 1/3 of the volume, precipitation with diethylether is carried out, yield: 6.0 g (76%). Example 6: Synthesis of CH3- (CH2) 7-SO2-Lys-Thr-Ser-Orn-Ser x 2 TFA (6): 2 g (2.2 mmol) of 5a is dissolved in DMF (20 ml) and stirred with 0.48 g (2.3 mmol) of 1-octanesulfochloride and 0.48 g (4,0 mmol) of DIPEA for 10 h at RT. After evaporation of the solvent, the crude product is stirred with 59 ml of TFA, 1.25 ml of water and 1.25 ml of triisopropylsilan for 1 h at RT. After reduction to 1/3 of the volume, precipitation with diethylether and purification over Sephadex LH20® are carried out, yield: 1.4 g (70%). - 20 - The peptide or conjugate can also be protonized with an inorganic acid, e.g. HC1, HBr, H2SO4 or H3PO4, or with an organic acid, e.g. formic acid, oxalic acid or tartaric acid, leading to corresponding salts of 6. Example 7: H-Dab-Ser-OH x 2 AcOH According to the described solid-phase protocol from Example 5a, the obtained H-Dab-Ser-OH x 2 TFA (3,0 g, 6.90 mmol) is analogously transformed in the acetate salt over an ion exchanger, yield 2.0 g (90.0%). The following compounds can also be synthesized according to the methods described in Examples 5-7: 15 Table 5: - 21 - - 22 -CLAIMS: 1. Oligopeptides and derivatives thereof, peptide analogs and derivatives thereof, as well as pharmaceutically acceptable salts of these compounds, thereby characterized that these compounds correspond to general formula (I) wherein R1 represents H, -C(O)-R7, -SO2-R7, -C(O)-OR7 or -C(O)-N(R7)2 R2 represents, independent of one another, H or-(C1-C4)-alkyl, R3 and R6 represent, independent of one another, -(CH2)q-N(R1)R8 R4 and R5 represent, independent of one another, -CH2-OR2, -CH(CH3)OR8 or -CH2-CH2-OR8, R7 represents hydrogen, (C1-C18)-alkyl optionally substituted once or several times, independent of one another, with halogen, hydroxy, carboxyl, amino, mercapto, 1,2-dithiolanyl, and/or sulfo; optionally substituted (C-r C19)-alkenyl; phenyl-(C1-C4)-alkyl, whose phenyl radical is optionally substituted with amino in the para position; or R8 represents H, -(C1-C4)-alkyl, -C(O)-R7, -C(O)-OR7, -C(O)-N(R7)2 or -SO2-R7 X represents oxygen (-O-) or-NH-; or XR7, with X = O, also represents the esters of a-tocopherol, tocotrienol or retinol or the carboxylic acid (with R7 = H), m, n, p represent, independent of one another, zero or 1, and q in R3 and R6 represents, independent of one another, an integer from 1 to 4, with the provision that the following conditions do not simultaneously occur: R4 = -CH(CH3)-OH and R5 = -CH(CH3)-OH and R6 = -(CH2)4-NH2. -23- 2. Compounds as claimed in claim 1, wherein the following conditions do not simultaneously occur: R4 = -CH2-OH or -CH(CH3)-OH and R5 = -CH(CH3)- OH and R6 = -(CH2)4-NH2; preferably that the following conditions do not simultaneously occur: R2 = H and R4 = -CH2-OH or -CH(CH3)-OH and R5 = -CH(CH3)-OH and R6 = -(CH2)4-NH2. 3. Compounds as claimed in claim 1 or 2, wherein the residue £R1(N(RZ) CH(R3)C(O)-] is derived from lysine. 4. Compounds as claimed in one of the claims 1-3, wherein the residue [-N(R2)CH(R4)C(O)-] at the position [-N(R2)CH(R4)C(O)-N(R2)CH(R5)C(O)-j is derived from threonine. 5. Compounds as claimed in one of the claims 1-4, wherein the residue [-N(R2)CH(R5)C(O)-] is derived from threonine. 6. Compounds as claimed in one of the claims 1-5, wherein the residue [-N(R2)CH(R6)C(O)-] is derived from ornithine, 2,4-diaminobutyric acid, and 2,3-diaminbpropionic acid. 7. Compounds as claimed in one of the claims 1-6, wherein the residue [- (N(R2)CH(R4)C(O)-XR7] is derived from serine. 8. Compounds as claimed in one of the claims 1-7, wherein they contain one of the following sequences: Sequence 1: -Ser-Ser-Orn- Sequence 2: -Thr-Thr-Orn- Sequence 3: -Thr-Thr-Dab- Sequence 4: -Thr-Thr-Dap- -24- 9. Compounds as claimed in one of the claims 1-8, wherein they contain one of the following sequences: -Ser-Ser-Orn-, Lys-Thr-Thr-Orn-Ser, Lys-Thr- Thr-Dab-Ser or Lys-Thr-Thr-Dab-Ser, as well as the sequences correspondingly derivatized with the substituents R1, R2, R7 and R8. 10. Compounds as claimed in one of the claims 1-9, wherein alkyl in R2 and/or Re represents, independent of one another, methyl, ethyl and propyl, preferably methyl; and in R1 and/or R7 alkyl has 1 to 4 or 8 to 22 C atoms, preferably 1 or 2, or 14 to 17 C atoms, respectively. 11. Compounds as claimed in one of the claims 1-10, wherein the compounds of formula (I) together with acids form mono- or polyvalent, homogeneous or mixed salts, preferably with inorganic acids, or with appropriate organic aliphatic saturated or unsaturated carboxyfic acids, or with aromatic carboxylic acids, or with aromatic-aliphatic carboxylic acids, or with heteroaromatic carboxylic acids, or with aliphatic or aromatic sulfonic acids, preferably with acetic acid and/or lactic acid. 12. Compounds as claimed in one of the claims 1-11, wherein they are present as isomeric forms and mixtures thereof, and as mixtures of rotamers. 13. Compounds as claimed in one of the claims 1-12, wherein R1 represents hydrogen, -C(O)-R7 or -SO2-R7, preferably -C(O)-R7 or hydrogen R2 represents, independent of one another, hydrogen or methyl, R3 and R6 represent, independent of one another, -(CH2)q-NH2. R4and R5 represent, independent of one another, -CHz-OH, -CH(CH3)OH or -CHVCHrOH, R7 represents hydrogen, methyl, ethyl, propyl, n-butyl, n-pentyl, n-hexyl, n- heptyl, n-octyl, n-nonyl, n-undecanyl, n-dodecanyl, n-tridecanyl, n- tetradecanyl, n-pentadecanyl, n-hexadecanyl, n-heptadecanyl, n-octadecanyl, n-nonadecanyl, isopropyl, tert.butyl, isobutyl, sec.butyl, isoamyl, phenyl, t- -25- butylphenyl, tolyl, 1- or 2-naphthyl, perfluorobutyl, pentadecafluoroheptyl, (+)- or (-)-bornan-2-onyl, 8(2)-heptadecenyl, 8(Z),11(Z)-heptadecadienyl, 4(Z),7 (Z),10(Z),13(Z)-nonadecatetraenyl or 8(Z)-11-hydroxyoctadecenyl, 1,2- dithiolanyl or (Ci-Ci9)-alkyl substituted with amino in u> position, or phenyl optionally substituted with methyl, amino or halogen in ortho and/or para position, preferably R7 as a part of XR7 represents hydrogen, methyl, ethyl and/or R7 as a part of R1 represents an alkyl residue with 14 to 17 C atoms. R8 represents hydrogen or methyl, X represents oxygen or -NH-, preferably oxygen, XR7, with X = O, represents the esters of a-tocopherol, tocotrienol or retinol or the carboxylic acid (with R7 = H), preferably the carboxylic acid, m, n, p represent, independent of one another, zero or 1, and q in R3 and R6 represents, independent of one another, 1, 2, 3 or 4. 14. Compounds as claimed in one of the claims 1-13, wherein R7-C(O)- represents the residue of a saturated or unsaturated fatty acid with 6, 8, 10, 12, 14, 16 or 18 C atoms, preferably the corresponding residue of a saturated fatty acid, preferably the corresponding residue of the caprylic acid, lauric acid, myristic acid, palmitic acid and/or stearic acid. 15. Compounds of formula (I): H-Dap-Ser-OHx2TFA Palm-Om-Ser-OH x TFA Palm-Orn-N-Me-Ser-OH x TFA PalnvDab-Ser-OH x TFA : Laurinoyl-Lys-Ser-OH x TFA Palm-Lys-Ser-OH x TFA O!eoyl-Lys-Ser-OH x TFA Octadecyi-NH-C(O)-Lys-Ser-Ser-Orn-Ser-OH x 2AcOH Hexadecyl-NH-C{O>-Lys-Ser-Ser-Om-Ser-OH x 2AcOH Tetradecyl-NH-C(O)-Lys-Ser-Ser-Orn-Ser-OH x 2AcOH Palm-Lys-Ser-Ser-Orn-Ser-OH x 2AcOH -26- 16. Compounds of formula (I): Palm-Lys-Thr-Thr-Dap-Ser-OH x 2AcOH Pa!m-I_ys-Thr-Thr-Dab-Ser-OH x 2AcOH 17. Compounds of formula (I): Laurinoyl-Lys-Thr-Thr-Orn-Ser-OH x 2AcOH Myristinoyl-Lys-Thr-Thr-Orn-Ser-OH x 2AcOH Stearinoyl-Lys-Thr-Thr-Orn-Ser-OH x 2AcOH Palmitoleinoyl-Lys-Thr-Thr-Orn-Ser-OH x 2AcOH Oleoyl-Lys-Thr-Thr-Orn-Ser-OH x 2AcOH Eicosaenoyl-Lys-Thr-Thr-Om-Ser-OH x 2AcOH Palm-Lys-Thr-Thr-Orn-Thr-OH x 2AcOH Palm-Lys-Thr-Thr-Orn-Ser-OH x 2AcOH Palrn-Lys-Thr-Thr-Orn-N-Me-Ser-OH x 2AcOH Palm-Lys-Thr-Thr-N-Me-Orn-Ser-OH x 2AcOH PalrrvLys-Thr-N-Me-Thr-Orn-Ser-OH x 2AcOH Palm-Lys-N-Me-Thr-Thr-Orn-Ser-OH x 2AcOH Palm-N-Me-Lys-Thr-Thr-Orn-Ser-OH x 2AcOH Palm-lys-N-Et-Thr-Thr-Orn-Ser-OH x 2AcOH Palm-Lys-N-Pr-Thr-Thr-Orn-Ser-OH x 2AcOH C8H,5-SOz-Lys-Thr-Thr-Orn-Ser-OH x 2AcOH CieHjrSOr-Lys-Thr-Thr-Orn-Ser-OH x 2AcOH C8F15-C(O)-Lys-Thr-Thr-Orn-Ser-OH x 2AcOH H-Lys-Thr-Thr-Orn-Ser-ORetinyl x 3AcOH 18. Method for the synthesis of the compounds as claimed in one of the claims 1-17, which comprises completely building up the compound of formula (I) by using methods known per se in peptide chemistry, optionally splitting the remaining protective group(s) and optionally acylating a free amino group and/or transforming the obtained compound in an acid addition salt and/or an obtained acid addition salt in the corresponding conjugate base or in another salt. -27- 19. Composition as claimed in one of the claims 1-17 as a pharmaceutical, preferably dermopharmaceutical and/or cosmetic active, in particular for increasing the production of collagen and fibronectin in human skin. 20. Composition as claimed in one of the claims 1-17 for the preparation of dermopharmaceutically and/or cosmetically active compositions, in particular to enhance wound healing and hydration, as skin care products, in particular to prevent the formation and aggravation of wrinkles and against all consequences of natural or accelerated (sun rays, pollution) skin aging. 21. Dermopharmaceutically and/or cosmetically active composition that contains at least one compound as claimed in one of the claims 1-17, preferably in a quantity ranging from 0.5 ppm to 5,000 ppm (w/w), preferably between 1 ppm and 1000 ppm (w/w), calculated on the weight of the compound of the present invention and of the bulk material(s). 22. Composition as claimed in claim 21, wherein it can be in the form of a solution, a dispersion, an emulsion or encapsulated in carriers, preferably in macrocapsules, microcapsules or nanocapsules, in liposomes or chylomicrons, or enclosed in macro-, micro- or nanoparticles or in microfungi or adsorbed on powdered organic polymers, talc, bentonite and further inorganic carriers. 23. Composition as claimed in claim 21, wherein it can be in the form of an emulsion, a milk, a lotion, an ointment, a gelatinous and viscous, lifting and emulsifying polymer, a pomade, a shampoo, a soap, a gel, a powder, a stick, a spray, a body oil, a face mask or a plaster for transdermal application. 24. Composition as claimed in one of the claims 21-23, wherein it contains commonly used ingredients selected among the group comprising: extraction lipids and/or synthesis lipids, gelatinous and viscous, lifting and emulsifying polymers, water- or fat-soluble active agents, plant extracts, tissue extracts, -28- marine extracts, sun protection agents, antioxidants, moisturizers and barrier agents and/or skin-revitalizing actives. 25. Composition as claimed in one of the claims 19-21 as aN dermopharmaceutically and/or cosmetically active agent, in particular to increase the production of collagen and fibronectin in human skin, to enhance hydration, as a skin care product, in particular to prevent the formation and aggravation of wrinkles and against all consequences of natural and accelerated (sun rays, pollution) skin aging. The invention relates to oligopeptides and derivatives thereof, to peptide analogs and deriva-tives thereof and to pharmaceutically acceptable salts of the compounds, which correspond to genera] formula (I), wherein: Rl represents H, -C(O)-R7, -SO2-R7, -C(O)-OR7 or -C(O)-N(R7)2; R2 represents, independent of one another, H or -(C1-C4) alkyl; R3 and R6 represent, independent of one another, -(CH2)q-N(R1)R8; R4 and R5 represent, independent of one another, CH2-OR2, -CH(CH3)OR8 or CH2-CHrOR8; R7 represents hydrogen, optionally substituted (C1-C19) alky], optionally substituted C1-C19 alkenyl, phenyl-C1-C4 alkyl whose phenyl radical is optionally substituted with amino in the p position; R8 represents H, -(C1-C4) alky], -C(O)-R7, -C(O)-OR7, -C(O)-N(R7)2 or -SC2-R7; X represents oxygen (-O-) or -NH- or; XR7, with X = O, also represents the esters of a-tocopherol, tocotrienol or retinol or the carboxylic acid (with R7 = H); m, n, p represent, independent of one another, zero or 1, and;q in R3and in R6 represents, independent of one another, an integer from 1 to 4, with the provision that the following conditions do not simultaneously occur R4 = -CH (CH3) -OH and R5 = -CH (CH3) -OH and R6 = -(CH2)4-NH2. The invention also relates to dermopharmaceutically and cosmetically active compositions containing at least one compound of formula (I).

Full Text

- 1 -
Dermopharmaceutically and cosmetically active oligopeptides
The present invention relates to pharmaceutically, dermopharmaceutically and cosmetically active oligopeptides, to derivatives thereof, to peptide analogs and derivatives thereof as well as to the use thereof in dermopharmaceutically and cosmetically active compositions.
The basic mechanism of skin aging is known to take place in the extracellular matrix, the so-called basal lamella/ when situated at the intersection between epithelium and connective tissue. Regeneration of the extracellular matrix is highly important as it considerably influences the behaviour of those cells that are in contact with it, in particular their growth, migration, proliferation, form and functions. An age-related reduction of collagen synthesis by fibroblasts occurs in this extracellular matrix, the consequence of which being a reduced number of chemical substances secreted by these cells. As skin proteins consist by approx. 80% of collagen, already a small natural decrease of the collagen concentration in the tissue may have clear consequences on the mechanical and physiological properties of skin.
Katayama et al. (The Journal of Biological Chemistry, Vol. 268, No. 14, pages 9941-9944, 1993) found that the minimal subfragment sequence for stimulating collagen and fibronectin is represented by the pentapeptide Lys-Thr-Thr-Lys-Ser. Sequences with four amino acids or less have a slighter or no stimulating effect.

- 2 -
The European patent application WO 00/15188 describes the effect of the palmitoylated pentapeptide Palm-Lys-Thr-Thr-Lys-Ser as a component tor treating skin aging, accelerating wound healing and improving skin moisturizing.
It has been found that selected, new oligopeptides and derivatives thereof as well as peptide analogs and derivatives thereof (in the following referred to as ,,compounds of the present invention") are surprisingly highly pharmaceutically and/or cosmetically effective and are particularly appropriate for use in dermopharmaceutically and/or cosmetically effective compositions. The compounds of the present invention diffuse rapidly and in sufficient concentration through the cell membrane up to the intracellular site of action, where they lead to a clearly increased production of collagen and fibronectin. Thus, the compounds of the present invention exert a surprisingly positive and stimulating effect on the extracellular matrix which decisively influences the mechanical and physiological appearance of skin. In particular, the compounds of the present invention induce a much more rapid and stronger stimulation of collagen synthesis than known so far for other compounds from the state of the art. The quicker and stronger stimulation of collagen synthesis by the compounds of the present invention is probably the result of a synergic effect which is obtained by reduction, of the molecular mass, introduction of N-methyl groups in amino acids and modification of amino acids with, e.g., fatty acid esters. However, the present invention is not bound to this explanation.

- 3 -
The present invention is defined in the claims and relates in particular to selected, new oligopeptides and derivatives thereof, peptide analogs and derivatives thereof, as well as pharmaceutically acceptable salts of these compounds, thereby characterized that these compounds correspond to general formula (I)

wherein
R1 represents H, -C(O)-R7, -SO2-R7, -C(0)-OR7 or -C (0) -N (R7) 2,
R2 represents, independent of one another, H or -{C1-C4)-
alkyl,
R3, R6 represent, independent of one another, - (CH2)q-N (R1) R8,
R4, R5 represent, independent of one another, -CH2-OR2,
CH(CH3)OR8 or -CH2-CH2-OR8,
R7 represents hydrogen, (C1-C19)-alkyl optionally substituted
once or several times, independent of one another, with
halogen, hydroxy, carboxyl, amino, mercapto, 1,2-dithiolanyl,
and/or sulfo; optionally substituted (C1-C19)-alkenyl; phenyl-
{C1-C4)-alkyl, whose phenyl radical is optionally substituted
with amino in the para position; or
R8 represents H, - (C1-C4) -alkyl, -C (0) -R7, -C (0) -OR7, -C (0) -
N(R7)2 or -SO2-R7
X represents oxygen (-0-) or -NH-; or
XR7, with X = 0, also represents the esters of a-tocopherol,
tocotrienol or retinol or the carboxylic acid (with R = H) ,
m, n, p represent, independent of one another, zero or 1 and

- 4 -
q in R3 and R6 represents, independent of one another, an integer from 1 to 4, with the provision that the following conditions do not simultaneously occur: R4 = -CH{CH3)-OH and R5 = -CH(CH3)-OH and R6 = ~(CH2)4-NH2.
Preferably, the following conditions do not simultaneously occur: R4 = -CH2-OH or -CH(CH3)-OH and R5 = -CH(CH3)-OH and R6 = -(CH2)4-NH2. Preferably, the following conditions do not simultaneously occur: R2 = H and R4 = -CH2-OH or -CH (CH3) -OH and R5 = -CH The compounds of "formula (I) comprise dipeptides, tripeptides, tetrapeptides and pentapeptides of the corresponding amino acids and derivatives thereof according to the definitions of R1, R2, R7 and R8, as well as corresponding peptide analogs.
The amino acid residues in general formula (I), which contain the substituents R3 or R6, are derived from lysine (Lys) , ornithine (Orn) , 2,4-diaminobutyric acid (Dab) or 2,3-diaminopropionic acid (Dap) and are residues of these amino acids or amino acid derivatives.
The amino acid residues in general formula (I), which contain the substituents R4 or R5, are derived from serine (Ser) , threonine (Thr), homo serine [H2N-CH ( (CH2) 2-0H)COOH, (HSe)] and are residues of these amino acids or amino acid derivatives.
The following table shows from which amino acids the compounds of the above formula (I) are derived:

- 5

The residue [R1 (N (R2) CH (R3) C (0) -] is preferably derived from
lysine.
The residue [-N (R2) CH (R4) C (0) -] at position [-N N (R2)CH (R5)C(0)-] is preferably derived from threonine.
The residue [-N (R2) CH (R5) C (0)-] is preferably derived from
threonine.
The residue [-N (R2) CH (R6) C (0) -] is preferably derived from
ornithine, 2,4-diaminobutyric acid (Dab), and 2,3-diaminopro-
pionic acid (Dap).
The terminal residue [- derived from serine.
The compounds of formula {I) preferably contain the following
sequences:
Sequence 1: -Ser-Ser-Orn-
Sequence 2: -Thr-Thr-Orn-
Sequence 3: -Thr-Thr-Dab-
Sequence 4: -Thr-Thr-Dap-
The compounds with the sequences -Ser-Ser-Orn-, Lys-Thr-Thr-
Orn-Ser, Lys-Thr-Thr-Dab-Ser and Lys-Thr-Thr-Dab-Ser, as well
as the sequences correspondingly derivatized with the
substituents R1, R2, R7 and R8 are particularly preferred.

- 6 -
Further preferred polypeptides enclosed by formula {I) are mentioned in the text.
Preferred compounds of formula (I) are also those wherein m = zero, when n or p = zero.
The terms ,,peptides" and ,,oligopeptides" above all comprise naturally occurring amino acids, peptides and oligopeptides, respectively. Peptide analogs mean synthetically modified amino acids, peptides and oligopeptides, respectively, e.g. with a methyl group at the nitrogen atom (CH3-N=) . Derivatives within the present invention particularly mean amino acids, peptides and oligopeptides, respectively, the terminal amino group or carboxyl group of which has been further converted, e.g. wherein the terminal carboxyl group has been esterified.
The compounds of formula (I) are particularly appropriate as pharmaceutical, dermopharmaceutical and/or cosmetic active ingredients for the preparation of pharmaceutically, dermopharmaceutically and/or cosmetically active compositions, in particular for increasing the collagen and fibronectin production in human skin.
Moreover, the present invention relates to a method for preparing the compounds of the present invention and salts thereof and their use as pharmaceutical, dermopharmaceutical and/or cosmetic active ingredients, as well as pharmaceutically, dermopharmaceutically and/or cosmetically active compositions which contain at least one compound of the present invention.

- 7 -
Furthermore, the present invention relates to the use of the compounds of the present invention for preparing a wound healing- and moisturizing-stimulating drug as well as to a method for delaying or treating skin aging, in particular the formation of wrinkles, which comprises applying a compound of the present invention and/or a composition of the present invention on the skin.
The above used, general terms are defined as follows:
Halogen means chlorine, bromine or iodine, preferably fluorine.
Alkyl, as a group per se or as a structural element of an alkoxy function, comprises linear as well as branched alkyl groups. Examples thereof are methyl, ethyl, propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-undecanyl, n-dodecanyl, n-tridecanyl,, n-hexadecanyl, n-heptadecanyl, n-octadecanyl or n-nonadecanyl as unbranched residues and isopropyl, tert.butyl, isobutyl, sec.butyl, isoamyl as branched residues. R2 and/or R8 as alkyl preferably means methyl, ethyl and propyl, preferably methyl. If R7 as a part of R1 means or contains an alkyl residue, it preferably represents alkyl with 8 to 22 C atoms, preferably with 14 to 17 C atoms. If XR7 contains an alkyl residue, it preferably means alkyl with 1 to 22 C atoms, preferably with 1 to 4 C atoms.
Alkenyl has the denotation of a mono- or poly-unsaturated, optionally substituted alkyl group, such as e.g. 8 (Z) -heptadecenyl, 8(Z), 11 (Z)-heptadecadienyl, 4 (Z),7(Z),10(Z), 13(Z)-nonadecatetraenyl, 8(Z)-11-hydroxyoctadecenyl.

- 8 -
-Tocopheryl means (D)-, The compounds of formula (I) together with acids can form mono- or polyvalent, homogeneous or mixed salts, e.g. with inorganic acids, such as hydrochloric acid, bromhydric acid, sulfuric acid or phosphoric acid; or with appropriate organic aliphatic saturated or unsaturated carboxylic acids, e.g. aliphatic mono- or dicarboxylic acids, such as formic acid, acetic acid, trifluoroacetic acid, trichloroacetic acid, propionic acid, glycolic acid, succinic acid, fumaric acid, malonic acid, maleic acid, oxalic acid, phthalic acid, citric acid, lactic acid or tartaric acid; or with aromatic carboxylic acids, such as benzoic acid or salicylic acid; or with aromatic-aliphatic carboxylic acids, such as mandelic acid or cinnamic acid; or with heteroaromatic carboxylic acids, such as nicotinic acid; or with aliphatic or aromatic sulfonic acids, such as methanesulfonic acid or toluenesulfonic acid. Dermatologically tolerated salts, in particular salts with acetic acid and/or lactic acid, are preferred.
The compounds of general formula (I) also comprise the possible isomeric forms as well as mixtures thereof, e.g. racemic mixtures and mixtures of rotamers.
The amino acids mentioned in formula (I) can have an L or D configuration, or represent a mixture of both configurations.

- 9 -
In particular, Thr may also represent the isomeric forms allo-Thr, D-Thr or D-allo-Thr or a mixture of Thr with D-Thr or allo-Thr with D-allo-Thr at the respective position in the sequence.
Among the compounds of formula (I), the following denotations or the following groups of compounds, respectively, are preferred, wherein
R1 represents hydrogen, -C{O)-R7, -SO2-R7, -C(O)-OR7 or -C(0)-N(R7)2, preferably wherein R1 represents hydrogen, -C(O)-R7 or -SO2-R7, preferably hydrogen or -C(O)-R7
R2 represents, independent of one another, hydrogen or methyl R3, R6 represent, independent of one another, - R7 preferably represents hydrogen, methyl, ethyl, propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-undecanyl, n-dodecanyl, n-tridecanyl, n-tetradecanyl, n-pentadecanyl, n-hexadecanyl, n-heptadecanyl, n-octadecanyl or n-nonadecanyl, isopropyl, tert.butyl, isobutyl, sec.butyl, isoamyl, phenyl, t-butylphenyl, tolyl, 1- or 2-naphthyl, perfluorobutyl, pentadecafluoroheptyl, ( + )- or (-)-bornan-2-onyl, 8(Z)-heptadecenyl, 8(Z),11
- 10 -
R8 represents hydrogen, C1-C4-alkyl or -C(O)-R7, preferably
hydrogen or methyl.
X represents oxygen, -NH-, preferably oxygen,
XR , with X = O, also represents the esters of ct-tocopherol,
tocotrienol or retinol or the carboxylic acid (with R7 = H),
preferably the carboxylic acid,
m, n, p represent, independent of one another, zero or 1, and
q in R3 and R6 represents, independent of one another, the
integer 1, 2, 3 or 4.
R7-C(O)- most preferably represents the residue of a saturated or unsaturated fatty acid with 6, 8, 10, 12, 14, 16 or 18 C atoms, preferably the corresponding residue of a saturated fatty acid, preferably the corresponding residue of
caprylic acid [CH3- (CH2) 6-C Representative examples of compounds of formula (I) are listed in Table 5 (after Example 7).
The compounds of the present invention can be manufactured according to methods known per se in peptide chemistry. The preferred procedure comprises fully assembling the compound of the present invention, e.g. a compound of formula (I) , optionally splitting off the remaining protective group(s) and optionally acylating a free amino group and/or converting the obtained compound into an acid addition salt and/or an obtained acid addition salt into the corresponding conjugate base or into another salt.

- 11 -
The compounds of the present invention can be used for the preparation of a dermopharmaceutically and/or cosmetically active composition. Such compositions contain an effective quantity of at least one compound of the present invention or a salt thereof, in the range from 0.5 ppm to 5,000 ppm (w/w), preferably between 1 ppm and 1000 ppm (w/w) , calculated on the weight of the compound of the present invention and of the bulking agent(s). The compounds of the present invention can be used as a solution, a dispersion, an emulsion or encapsulated in carriers, such as e.g. in macro-, micro- or nanocapsules, in liposomes or chylomicrons, or enclosed in macro-, micro- or nanopar tides or in micro fungi or adsorbed on powdered organic polymers, talc, bentonite and further inorganic carriers.
The compounds of the present invention can be used in any galenic form, such as emulsions, milks, lotions, ointments, gelatinous and viscous, lifting and emulsifying polymers, pomades, shampoos, soaps, gels, powders, sticks, sprays, body oils, face masks or a plaster for transdermal application.
The compounds of the present invention can be used with any further, commonly used ingredient, such as extraction lipids and/or synthetic lipids, gelatinous and viscous, lifting and emulsifying polymers, water- or fat-soluble active agents, plant extracts, tissue extracts, marine extracts, sun-protective agents, antioxidants, water-retaining and barrier substances as well as skin-revitalizing agents.
The compounds of the present invention are used in cosmetic
applications to enhance wound healing_and hy_dx_at_ion, and in
all skin care products, in particular against the formation

- 12 -
and aggravation of wrinkles and against all consequences of natural or accelerated (sun rays, pollution) skin aging.
The compounds of the present invention as well as the cosmetic and dermopharmaceutical compositions containing same can be used for the preparation of a drug to promote wound healing and hydration, and for all skin care products, in particular against the formation and aggravation of wrinkles and against all consequences of natural or accelerated (sun rays, pollution) skin aging.
The present invention also relates to a method for delaying or treating skin aging, in particular wrinkle formation, which comprises the application on the skin of a compound of the present invention. Analogously, the present invention relates to a method for accelerating wound healing and/or improving skin hydration, which comprises the application on the skin of a compound of the present invention.
The following examples illustrate the invention without
limiting its scope. The following abbreviations are used in
the text and in Examples 1-7:
AcOH: Acetic acid
Boc: tert.-Butyloxycarbonyl
Dab: 2,4-Diaminobutyric acid
Dap: 2,3-Diaminopropionic acid
DBU: 1,8-Diazabicyclo[5,4,0]undec-7-ene(1,5-5)
DIPEA: Diisopropylethylamine
DMEM: Dulbecco's Modified Eagle Medium
Et: Ethyl
FCS: Fetal Calf Serum
HSe: Homoserine

- 13 -
Hyp: Hydroxyproline
Gly: Glycine
Lipoyl: a-D,L-Lipoic acid
Me: Methyl
MEM: Minimal Essential Medium
N-Me-Ser: N-Methyl-Serine
N-Me-Thr: N-Methyl-Threon.ine
NMM: N-Methylmorpholine
Orn: Ornithine
Palm: Palmitoyl
PBS: Phosphate buffered saline
Pr: Propyl
RT: Room temperature
TBTU: O-(Benzotriazol-1-yl)-N,N,N' ,N'-tetramethyluronium
tetrafluoroborate
tBu: t-Butyl
TFA: Trifluoroacetic acid
TGF-p(beta)1: Transforming Growth Factor-beta(p)
Example 1: Determination of the stimulation of collagen synthesis type I+III in fibroblast cell cultures (ATCC CCL110) by treatment with the oligopeptide derivatives of the present invention.
Method:
The collagen I and III content in fibroblasts is measured with the Sirius Red microassay. The quantitative determination of collagen is carried out after 24 hours of incubation with the corresponding oligopeptide derivatives. The extracellularly accumulated collagen is determined. Vitamin C and TGF-beta-1 are used as positive controls.

- 14 -
Method:
ATCC CCL110 fibroblasts are incubated in culture medium at a density of approx. 125,000 cells/well in 6-well cell culture plates for 2 days (37°C/5%CO2) . Afterwards, the medium is discarded and washed twice with PBS, whereupon 1 ml of test medium with corresponding test substances is added. After . incubation with test substance under culture conditions (37°C/5%CO2) for further 24 hours, the extracellular collagen is measured with the Sirius Red assay.
Sirius Red assay extracellular:
After the incubation period, the total volume of test medium (1 ml) is transferred into a flat-bottom 24-well plate and dried overnight at 55°C. The samples are fixed with 1 ml/well of Bouin's fluid for 1 hour at room temperature (RT) . The fixing solution is discarded and the plates are washed 2-3 times with water. After drying of the plates, 1 ml of Sirius Red dye reagent is added.
The samples are shaken for 1 hour at RT on a microplate agitator at moderate intensity. Afterwards, the Sirius Red dye reagent is discarded and the plates are washed with 0.01N HCl. The tinted material is dissolved in 0.3 ml of 0.IN NaOH solution and shaken on a microplate agitator for 1 hour at Rf.
200 [il of solution is transferred into a flat-bottom 96-well plate and the optical density is measured at 540 nm against 0.1N NaOH solution as the blank.
Material:

- 15 -
Culture medium: MEM + 10% FCS + 100 IU/ml penicillin + 0.1
mg/ral streptomycin + 1 mM non essential amino acids + 1 mM
Na-pyruvate + 2 mM L-glutamine.
Test medium: DMEM without phenol red (AMIMED) + 100 IU/ml
penicillin + 0.1 mg/ml streptomycin + 80 ng/ml beta (p)-
aminopropionitrile.
Dilution of the substances:
Vitamin C 100 mM (SIGMA A4034) is diluted to 50 ng/ml in the
test medium.
Transforming growth factor TGF 1 1 ng/ml (SIGMA T1654) is
diluted to 0.1 ng/ml in the test medium.
The oligopeptide derivatives of the present invention are
prepared in a regular concentration of 10 mM and diluted to
50 fiM in the test medium.
Reagents for the Sirius Red microassay:
Sirius Red F3BA dye reagent as the stock solution 1 mg/ml in
saturated aqueous picric acid solution. Bouin's fluid: 15 ml
of saturated aqueous picric acid solution + 5 ml of
formaldehyde + 1 ml of acetic acid. The results are shown in
Table 1.
Table 1
Results, quantitative determination of collagen type I+III
after 24 hours:

- 16 -

Example 2: Determination of the fibronectin content after treatment with the oligopeptide derivatives of the present invention Method:
The fibronectin (laminin or collagen VII) content in the fibroblast cells is determined by immuno-dot blotting. Cultivation and incubation of the cells are carried out in the same way as described in Example 1. Afterwards, the cells are lysed and the lysates (0.5 ml) are blotted on a nitrocellulose sheet in a prepared bio-dot device. The sheets are then incubated with a specific primary antibody to human fibronectin according to the western blotting method. A conjugate with alkaline phosphatase is used as the secondary antibody. The intensity of the bands is visually determined semi-quantitatively after dying and stopping of the reaction. The results are shown in Table 2.
Table 2
Results, quantitative determination of fibronectin (or
laminin V or collagen type VII) after 24 hours of incubation:

- 17 -

Example 3: Formulation of an ointment
Method: Ingredients 1-5 (A) are heated to 70°C. Ingredients 6-7 (B) are heated to 75°C. Under stirring B is added to A, cooled to 50°C, homogenized and cooled to 30°C. Afterwards, ingredients 8-9 (C) and ingredient 10 (D) are added one after the other and stirred cold. The formulations are shown in Table 3.
10 Table 3

Example 4: Formulation of a gel
Method: Ingredients 2-6 (A) are dissolved one after the other in deionized water. After adjusting the pH to 6.0 with ingredient 7 (B), ingredient 8 (C) is added. The formulations are shown in Table 4.

- 18
Table 4
Examples 5-7:
The following embodiments 5-7 describe the synthesis of the compounds of formula (I) of the present invention and of salts of such compounds. The eluates and products obtained according to the examples are analysed using proton NMR, HPLC-electrospray MS or elementary analysis. The compounds can be manufactured according to known methods described hereinafter (general instructions from M. Bodanszky "The Practice of Peptide Synthesis", Springer, 2nd Edition, 1994). Accordingly, the amino acid, e.g. serine, is bound to a resin at the carboxy terminal end in a solid-phase synthesis, whereby its amino group is protected by a protective group, e.g. by the Fmoc protective group. The side chain is protected with, e.g., Boc or t-butyl. If necessary, the protective groups are selectively split off in order to link up the further amino acid derivatives with the reagents commonly used in peptide synthesis until the desired chain is completely built up. Afterwards, the peptide or peptide analog, respectively, is split off from the resin at the carboxy terminal end and this carboxy terminal end is

- 19 -
connected with varying C(O)-R7, SO2-R7, C(O)-OR7 or C(O)-N(R7)2 residues, whereupon the protective groups are removed.
Example 5: H-Lys-Thr-Ser-Orn-Ser x 3 TFA
Synthesis of H-Lys(Boc)-Thr(tBu)-Ser(tBu)-Orn(Boc)-Ser(tBu)-
OH x TFA (5a):
In a typical solid-phase synthesis protocol, the pentapeptide
is obtained by repetitive coupling of 18.7 g {14.0 mmol,
charge: 0.75 mmol/g) of commercial H-Ser(tBu)-chlorotrityl
resin with 16.8 mmol of the amino acids Fmoc-Orn (Boc) -OH,
Fmoc-Thr(tBu)-OH (2x), Fmoc-Lys(Boc)-OH, 18 mmol TBTU, 33.6
mmol collidin and unblocking with 1% DBU in DMF (2x5 min) ,
splitting from the resin with 1% TFA in dichloromethane and
purification over Sephadex LH20®, yield: 9.3 g (64%).
Synthesis of H-Lys-Thr-Ser-Orn-Ser-OH x 3TFA (5b): 9.3 g of 5a is stirred for 1 hour at RT in a mixture composed of 59 ml of TFA, 1.25 ml of water and 1.25 ml of triisopropylsilan. After reduction to 1/3 of the volume, precipitation with diethylether is carried out, yield: 6.0 g (76%).
Example 6:
Synthesis of CH3- (CH2) 7-SO2-Lys-Thr-Ser-Orn-Ser x 2 TFA (6): 2 g (2.2 mmol) of 5a is dissolved in DMF (20 ml) and stirred with 0.48 g (2.3 mmol) of 1-octanesulfochloride and 0.48 g (4,0 mmol) of DIPEA for 10 h at RT. After evaporation of the solvent, the crude product is stirred with 59 ml of TFA, 1.25 ml of water and 1.25 ml of triisopropylsilan for 1 h at RT. After reduction to 1/3 of the volume, precipitation with diethylether and purification over Sephadex LH20® are carried out, yield: 1.4 g (70%).

- 20 -
The peptide or conjugate can also be protonized with an inorganic acid, e.g. HC1, HBr, H2SO4 or H3PO4, or with an organic acid, e.g. formic acid, oxalic acid or tartaric acid, leading to corresponding salts of 6.
Example 7: H-Dab-Ser-OH x 2 AcOH
According to the described solid-phase protocol from Example
5a, the obtained H-Dab-Ser-OH x 2 TFA (3,0 g, 6.90 mmol) is
analogously transformed in the acetate salt over an ion
exchanger, yield 2.0 g (90.0%).
The following compounds can also be synthesized according to
the methods described in Examples 5-7:
15 Table 5:

- 21 -

- 22 -CLAIMS:
1. Oligopeptides and derivatives thereof, peptide analogs and derivatives thereof, as well as pharmaceutically acceptable salts of these compounds, thereby characterized that these compounds correspond to general formula (I)

wherein
R1 represents H, -C(O)-R7, -SO2-R7, -C(O)-OR7 or -C(O)-N(R7)2 R2 represents, independent of one another, H or-(C1-C4)-alkyl, R3 and R6 represent, independent of one another, -(CH2)q-N(R1)R8 R4 and R5 represent, independent of one another, -CH2-OR2, -CH(CH3)OR8 or -CH2-CH2-OR8,
R7 represents hydrogen, (C1-C18)-alkyl optionally substituted once or several times, independent of one another, with halogen, hydroxy, carboxyl, amino, mercapto, 1,2-dithiolanyl, and/or sulfo; optionally substituted (C-r C19)-alkenyl; phenyl-(C1-C4)-alkyl, whose phenyl radical is optionally substituted with amino in the para position; or
R8 represents H, -(C1-C4)-alkyl, -C(O)-R7, -C(O)-OR7, -C(O)-N(R7)2 or -SO2-R7 X represents oxygen (-O-) or-NH-; or
XR7, with X = O, also represents the esters of a-tocopherol, tocotrienol or retinol or the carboxylic acid (with R7 = H), m, n, p represent, independent of one another, zero or 1, and q in R3 and R6 represents, independent of one another, an integer from 1 to 4, with the provision that the following conditions do not simultaneously occur: R4 = -CH(CH3)-OH and R5 = -CH(CH3)-OH and R6 = -(CH2)4-NH2.

-23-
2. Compounds as claimed in claim 1, wherein the following conditions do
not simultaneously occur: R4 = -CH2-OH or -CH(CH3)-OH and R5 = -CH(CH3)-
OH and R6 = -(CH2)4-NH2; preferably that the following conditions do not
simultaneously occur: R2 = H and R4 = -CH2-OH or -CH(CH3)-OH and R5 =
-CH(CH3)-OH and R6 = -(CH2)4-NH2.
3. Compounds as claimed in claim 1 or 2, wherein the residue £R1(N(RZ)
CH(R3)C(O)-] is derived from lysine.
4. Compounds as claimed in one of the claims 1-3, wherein the residue
[-N(R2)CH(R4)C(O)-] at the position [-N(R2)CH(R4)C(O)-N(R2)CH(R5)C(O)-j is
derived from threonine.
5. Compounds as claimed in one of the claims 1-4, wherein the residue
[-N(R2)CH(R5)C(O)-] is derived from threonine.
6. Compounds as claimed in one of the claims 1-5, wherein the residue
[-N(R2)CH(R6)C(O)-] is derived from ornithine, 2,4-diaminobutyric acid, and
2,3-diaminbpropionic acid.
7. Compounds as claimed in one of the claims 1-6, wherein the residue [-
(N(R2)CH(R4)C(O)-XR7] is derived from serine.
8. Compounds as claimed in one of the claims 1-7, wherein they contain
one of the following sequences:
Sequence 1: -Ser-Ser-Orn-
Sequence 2: -Thr-Thr-Orn-
Sequence 3: -Thr-Thr-Dab-
Sequence 4: -Thr-Thr-Dap-

-24-
9. Compounds as claimed in one of the claims 1-8, wherein they contain
one of the following sequences: -Ser-Ser-Orn-, Lys-Thr-Thr-Orn-Ser, Lys-Thr-
Thr-Dab-Ser or Lys-Thr-Thr-Dab-Ser, as well as the sequences
correspondingly derivatized with the substituents R1, R2, R7 and R8.
10. Compounds as claimed in one of the claims 1-9, wherein alkyl in R2
and/or Re represents, independent of one another, methyl, ethyl and propyl,
preferably methyl; and in R1 and/or R7 alkyl has 1 to 4 or 8 to 22 C atoms,
preferably 1 or 2, or 14 to 17 C atoms, respectively.
11. Compounds as claimed in one of the claims 1-10, wherein the
compounds of formula (I) together with acids form mono- or polyvalent,
homogeneous or mixed salts, preferably with inorganic acids, or with
appropriate organic aliphatic saturated or unsaturated carboxyfic acids, or
with aromatic carboxylic acids, or with aromatic-aliphatic carboxylic acids, or
with heteroaromatic carboxylic acids, or with aliphatic or aromatic sulfonic
acids, preferably with acetic acid and/or lactic acid.
12. Compounds as claimed in one of the claims 1-11, wherein they are
present as isomeric forms and mixtures thereof, and as mixtures of rotamers.
13. Compounds as claimed in one of the claims 1-12, wherein
R1 represents hydrogen, -C(O)-R7 or -SO2-R7, preferably -C(O)-R7 or
hydrogen
R2 represents, independent of one another, hydrogen or methyl,
R3 and R6 represent, independent of one another, -(CH2)q-NH2.
R4and R5 represent, independent of one another, -CHz-OH, -CH(CH3)OH or
-CHVCHrOH,
R7 represents hydrogen, methyl, ethyl, propyl, n-butyl, n-pentyl, n-hexyl, n-
heptyl, n-octyl, n-nonyl, n-undecanyl, n-dodecanyl, n-tridecanyl, n-
tetradecanyl, n-pentadecanyl, n-hexadecanyl, n-heptadecanyl, n-octadecanyl,
n-nonadecanyl, isopropyl, tert.butyl, isobutyl, sec.butyl, isoamyl, phenyl, t-

-25-
butylphenyl, tolyl, 1- or 2-naphthyl, perfluorobutyl, pentadecafluoroheptyl, (+)-
or (-)-bornan-2-onyl, 8(2)-heptadecenyl, 8(Z),11(Z)-heptadecadienyl, 4(Z),7
(Z),10(Z),13(Z)-nonadecatetraenyl or 8(Z)-11-hydroxyoctadecenyl, 1,2-
dithiolanyl or (Ci-Ci9)-alkyl substituted with amino in u> position, or phenyl
optionally substituted with methyl, amino or halogen in ortho and/or para
position, preferably R7 as a part of XR7 represents hydrogen, methyl, ethyl
and/or R7 as a part of R1 represents an alkyl residue with 14 to 17 C atoms.
R8 represents hydrogen or methyl,
X represents oxygen or -NH-, preferably oxygen,
XR7, with X = O, represents the esters of a-tocopherol, tocotrienol or retinol or
the carboxylic acid (with R7 = H),
preferably the carboxylic acid,
m, n, p represent, independent of one another, zero or 1, and
q in R3 and R6 represents, independent of one another, 1, 2, 3 or 4.
14. Compounds as claimed in one of the claims 1-13, wherein R7-C(O)-
represents the residue of a saturated or unsaturated fatty acid with 6, 8, 10,
12, 14, 16 or 18 C atoms, preferably the corresponding residue of a saturated
fatty acid, preferably the corresponding residue of the caprylic acid, lauric
acid, myristic acid, palmitic acid and/or stearic acid.
15. Compounds of formula (I):
H-Dap-Ser-OHx2TFA
Palm-Om-Ser-OH x TFA
Palm-Orn-N-Me-Ser-OH x TFA
PalnvDab-Ser-OH x TFA :
Laurinoyl-Lys-Ser-OH x TFA
Palm-Lys-Ser-OH x TFA
O!eoyl-Lys-Ser-OH x TFA
Octadecyi-NH-C(O)-Lys-Ser-Ser-Orn-Ser-OH x 2AcOH Hexadecyl-NH-C{O>-Lys-Ser-Ser-Om-Ser-OH x 2AcOH Tetradecyl-NH-C(O)-Lys-Ser-Ser-Orn-Ser-OH x 2AcOH Palm-Lys-Ser-Ser-Orn-Ser-OH x 2AcOH

-26-
16. Compounds of formula (I):
Palm-Lys-Thr-Thr-Dap-Ser-OH x 2AcOH Pa!m-I_ys-Thr-Thr-Dab-Ser-OH x 2AcOH
17. Compounds of formula (I):
Laurinoyl-Lys-Thr-Thr-Orn-Ser-OH x 2AcOH Myristinoyl-Lys-Thr-Thr-Orn-Ser-OH x 2AcOH Stearinoyl-Lys-Thr-Thr-Orn-Ser-OH x 2AcOH Palmitoleinoyl-Lys-Thr-Thr-Orn-Ser-OH x 2AcOH Oleoyl-Lys-Thr-Thr-Orn-Ser-OH x 2AcOH Eicosaenoyl-Lys-Thr-Thr-Om-Ser-OH x 2AcOH Palm-Lys-Thr-Thr-Orn-Thr-OH x 2AcOH Palm-Lys-Thr-Thr-Orn-Ser-OH x 2AcOH Palrn-Lys-Thr-Thr-Orn-N-Me-Ser-OH x 2AcOH Palm-Lys-Thr-Thr-N-Me-Orn-Ser-OH x 2AcOH PalrrvLys-Thr-N-Me-Thr-Orn-Ser-OH x 2AcOH Palm-Lys-N-Me-Thr-Thr-Orn-Ser-OH x 2AcOH Palm-N-Me-Lys-Thr-Thr-Orn-Ser-OH x 2AcOH Palm-lys-N-Et-Thr-Thr-Orn-Ser-OH x 2AcOH Palm-Lys-N-Pr-Thr-Thr-Orn-Ser-OH x 2AcOH C8H,5-SOz-Lys-Thr-Thr-Orn-Ser-OH x 2AcOH CieHjrSOr-Lys-Thr-Thr-Orn-Ser-OH x 2AcOH C8F15-C(O)-Lys-Thr-Thr-Orn-Ser-OH x 2AcOH H-Lys-Thr-Thr-Orn-Ser-ORetinyl x 3AcOH
18. Method for the synthesis of the compounds as claimed in one of the
claims 1-17, which comprises completely building up the compound of
formula (I) by using methods known per se in peptide chemistry, optionally
splitting the remaining protective group(s) and optionally acylating a free
amino group and/or transforming the obtained compound in an acid addition
salt and/or an obtained acid addition salt in the corresponding conjugate base
or in another salt.

-27-
19. Composition as claimed in one of the claims 1-17 as a pharmaceutical,
preferably dermopharmaceutical and/or cosmetic active, in particular for
increasing the production of collagen and fibronectin in human skin.
20. Composition as claimed in one of the claims 1-17 for the preparation of
dermopharmaceutically and/or cosmetically active compositions, in particular
to enhance wound healing and hydration, as skin care products, in particular
to prevent the formation and aggravation of wrinkles and against all
consequences of natural or accelerated (sun rays, pollution) skin aging.
21. Dermopharmaceutically and/or cosmetically active composition that
contains at least one compound as claimed in one of the claims 1-17,
preferably in a quantity ranging from 0.5 ppm to 5,000 ppm (w/w), preferably
between 1 ppm and 1000 ppm (w/w), calculated on the weight of the
compound of the present invention and of the bulk material(s).
22. Composition as claimed in claim 21, wherein it can be in the form of a
solution, a dispersion, an emulsion or encapsulated in carriers, preferably in
macrocapsules, microcapsules or nanocapsules, in liposomes or
chylomicrons, or enclosed in macro-, micro- or nanoparticles or in microfungi
or adsorbed on powdered organic polymers, talc, bentonite and further
inorganic carriers.
23. Composition as claimed in claim 21, wherein it can be in the form of an
emulsion, a milk, a lotion, an ointment, a gelatinous and viscous, lifting and
emulsifying polymer, a pomade, a shampoo, a soap, a gel, a powder, a stick,
a spray, a body oil, a face mask or a plaster for transdermal application.
24. Composition as claimed in one of the claims 21-23, wherein it contains
commonly used ingredients selected among the group comprising: extraction
lipids and/or synthesis lipids, gelatinous and viscous, lifting and emulsifying
polymers, water- or fat-soluble active agents, plant extracts, tissue extracts,

-28-
marine extracts, sun protection agents, antioxidants, moisturizers and barrier agents and/or skin-revitalizing actives.
25. Composition as claimed in one of the claims 19-21 as aN dermopharmaceutically and/or cosmetically active agent, in particular to increase the production of collagen and fibronectin in human skin, to enhance hydration, as a skin care product, in particular to prevent the formation and aggravation of wrinkles and against all consequences of natural and accelerated (sun rays, pollution) skin aging.
The invention relates to oligopeptides and derivatives thereof, to peptide analogs and deriva-tives thereof and to pharmaceutically acceptable salts of the compounds, which correspond to genera] formula (I), wherein: Rl represents H, -C(O)-R7, -SO2-R7, -C(O)-OR7 or -C(O)-N(R7)2; R2 represents, independent of one another, H or -(C1-C4) alkyl; R3 and R6 represent, independent of one another, -(CH2)q-N(R1)R8; R4 and R5 represent, independent of one another, CH2-OR2, -CH(CH3)OR8 or CH2-CHrOR8; R7 represents hydrogen, optionally substituted (C1-C19) alky], optionally substituted C1-C19 alkenyl, phenyl-C1-C4 alkyl whose phenyl radical is optionally substituted with amino in the p position; R8 represents H, -(C1-C4) alky], -C(O)-R7, -C(O)-OR7, -C(O)-N(R7)2 or -SC2-R7; X represents oxygen (-O-) or -NH- or; XR7, with X = O, also represents the esters of a-tocopherol, tocotrienol or retinol or the carboxylic acid (with R7 = H); m, n, p represent, independent of one another, zero or 1, and;q in R3and in R6 represents, independent of one another, an integer from 1 to 4, with the provision that the following conditions do not simultaneously occur R4 = -CH (CH3) -OH and R5 = -CH (CH3) -OH and R6 = -(CH2)4-NH2. The invention also relates to dermopharmaceutically and cosmetically active compositions containing at least one compound of formula (I).

Documents:

« Previous Patent

Next Patent »

Patent Number

206734

Indian Patent Application Number

00541/KOLNP/2004

PG Journal Number

19/2007

Publication Date

11-May-2007

Grant Date

10-May-2007

Date of Filing

23-Apr-2004

Name of Patentee

PENTAPHARM AG

Applicant Address

ENGELGASSE 109, CH-4052 BASEL,SWITZERLAND

Inventors:

#	Inventor's Name	Inventor's Address
1	LUDIN CHRISTIAN	GEMPENRING 4,CH-4147,AESCH,SWITZERLAND
2	HEIDL MARC	IM PROLI 9,79639 GRENZACH-WYHLEN,
3	ZIEGLER HUGO	IM BOHNACKER 15,CH-4108 WITTERSWIL,

PCT International Classification Number

C07K14/78

PCT International Application Number

PCT/CH02/00587

PCT International Filing date

2002-10-30

PCT Conventions:

#	PCT Application Number	Date of Convention	Priority Country
1	1986/01	2001-10-30	Switzerland